8-K: Outset Medical Reports Mixed Q1 2024 Results Amidst Restructuring

Outset Medical's first quarter results show revenue decline but improved gross margins and cost-cutting measures, alongside a workforce reduction.

Summary

• Outset Medical reported a revenue of $28.2 million for the first quarter of 2024, a decrease from $33.5 million in the same period last year.
• The decline in revenue was primarily due to a decrease in product revenue to $20.4 million.
• Service and other revenue increased by 36.1% to $7.7 million compared to $5.7 million in the first quarter of 2023.
• Recurring revenue from cartridges and services grew by 24% year-over-year.
• Total gross profit was $8.2 million, up from $6.4 million in the first quarter of 2023, with a gross margin of 29.2%, an increase from 19.2%.
• Non-GAAP gross margin improved to 31.1% from 20.3% in the first quarter of 2023.
• Operating expenses decreased by 10% to $45.1 million, including R&D expenses of $12.6 million, sales and marketing expenses of $21.0 million, and general and administrative expenses of $11.4 million.
• The company reported a net loss of $(39.9) million, or $(0.78) per share, compared to a net loss of $(44.0) million, or $(0.90) per share, for the same period in 2023.
• On a non-GAAP basis, the net loss was $(29.3) million, or $(0.57) per share, compared to a non-GAAP net loss of $(35.4) million, or $(0.72) per share for the same period in 2023.
• The company implemented a workforce reduction plan in May 2024, resulting in restructuring charges of $3.0 million in the first quarter of 2024.
• Outset reaffirmed its 2024 revenue guidance of $145 million to $153 million, representing 12% to 18% growth over 2023, and non-GAAP gross margin in the low-30% range for the full year, exiting the year in the mid-30% range for the fourth quarter.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive aspects like improved gross margins and cost reductions, the overall revenue decline and net loss temper the positive outlook. The workforce reduction also adds a negative element.

Positives

• Service and other revenue saw a substantial increase of 36.1% year-over-year.
• Recurring revenue from cartridges and services grew by 24% compared to the prior year.
• Gross margin improved significantly to 29.2% from 19.2% in the first quarter of 2023.
• Non-GAAP gross margin improved to 31.1% from 20.3% in the first quarter of 2023.
• Operating expenses decreased by 10% year-over-year.
• The net loss improved to $(39.9) million, or $(0.78) per share, compared to $(44.0) million, or $(0.90) per share, in Q1 2023.
• The company reaffirmed its 2024 revenue guidance of $145 million to $153 million.
• The company is aiming for cash-flow breakeven sooner than previously expected.

Negatives

• Total revenue decreased to $28.2 million from $33.5 million in the first quarter of 2023.
• Product revenue declined to $20.4 million.
• The company reported a net loss of $(39.9) million for the quarter.
• A workforce reduction plan was implemented, resulting in $3.0 million in restructuring charges.
• Cash and cash equivalents decreased from $68.5 million to $32.2 million.

Risks

• The company faces risks related to achieving its profitability goals and cash-flow breakeven.
• The company's ability to respond to and resolve any reports, observations or other actions by the Food and Drug Administration or other regulators in a timely and effective manner is a risk.
• Macroeconomic factors could impact the company, its customers, and suppliers.
• The company's reliance on forward-looking statements, which are subject to risks and uncertainties, is a risk.

Future Outlook

Outset reaffirmed its 2024 revenue guidance of $145 million to $153 million, representing 12% to 18% growth over 2023, and non-GAAP gross margin in the low-30% range for the full year, exiting the year in the mid-30% range for the fourth quarter. The company believes it is on a clear path to achieve cash-flow breakeven sooner than previously expected.

Management Comments

• Leslie Trigg, Chair and Chief Executive Officer, stated that the company is well positioned to capitalize on the $11 billion U.S. dialysis market opportunity.
• Leslie Trigg noted that Tablo's value proposition continues to resonate with acuteand home-care providers.
• Management believes that cost-reduction steps, combined with continued gross margin expansion and a strong recurring revenue foundation, provide a clear path to achieve cash-flow breakeven sooner than previously expected.

Industry Context

The company operates in the medical technology sector, specifically focusing on dialysis solutions. The announcement highlights the company's efforts to reduce costs and improve profitability in a competitive market. The company is targeting the $11 billion U.S. dialysis market.

Comparison to Industry Standards

• Outset Medical's gross margin improvement to 29.2% is a positive sign, but it still lags behind some established medical device companies with gross margins often exceeding 50%.
• Companies like Baxter International and Fresenius Medical Care, which are major players in the dialysis market, typically have higher revenue figures and established global distribution networks.
• Outset's focus on a single enterprise solution with Tablo is a differentiator, but it needs to demonstrate consistent revenue growth and profitability to compete effectively with larger, more established players.
• The company's recurring revenue growth of 24% is a positive indicator, as it suggests a growing installed base and customer loyalty, which is crucial for long-term success in the medical device industry.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the improved gross margins and cost-cutting measures.
• Employees are impacted by the workforce reduction plan.
• Customers may benefit from the company's focus on improving its technology and services.
• Suppliers may be affected by the company's cost-reduction efforts.
• Creditors will be monitoring the company's progress towards profitability.

Next Steps

• The company will continue to focus on improving operational efficiencies and reducing operating expenses.
• Outset will host a conference call on May 8, 2024, to discuss its first quarter 2024 financial results.
• The company will continue to execute its initiatives designed to expand gross margins.

Key Dates

Keywords

dialysis, medical technology, revenue, gross margin, operating expenses, net loss, workforce reduction, restructuring, Tablo, recurring revenue